AstraZeneca PLC (AZN)vsENvue Medical Inc. (FEED)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
FEED
ENvue Medical Inc.
$1.16
0.00%
HEALTHCARE · Cap: $4.96M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2300683% more annual revenue ($58.74B vs $2.55M). AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
FEED
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+8.4%
Fair Value
$2.96
Current Price
$1.16
$1.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -106.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : FEED
The strongest argument for FEED centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : FEED
The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
FEED carries more volatility with a beta of 2.10 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 30/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
ENvue Medical Inc.
HEALTHCARE · MEDICAL DEVICES · USA
ENvue Medical Inc. (FEED) is an innovative healthcare technology company dedicated to transforming patient care management with its advanced medical devices and comprehensive software solutions. By leveraging cutting-edge technology, ENvue Medical aims to enhance recovery processes and elevate health outcomes in diverse clinical environments. Its promising product pipeline, along with strategic partnerships, uniquely positions the company to seize the expanding opportunities within the healthcare sector, making it an attractive investment prospect for institutional investors focused on the evolving landscape of medical device innovation and digital health.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?